Mucosal Vaccines: Prevention of Caries and Periodontal Diseases.

Slides:



Advertisements
Similar presentations
Immunity to Infectious Diseases
Advertisements

Diseases of the gastrointestinal tract
Natural Defense Mechanisms. Immunology Unit. College of Medicine & KKUH.
Microbial Interactions with Humans
 Mucous membranes –Conjunctiva –Respiratory –Gastrointestinal tract –Urogenital  Skin –Abrasions or bite  Parenteral –Puncture or injection Portals.
Infectious Diseases of the Digestive System. GI Tract.
1 Slide #Dennis E. Lopatin, Ph.D. Molecular and Cellular Basis of Immune Protection of Mucosal Surfaces Dennis E. Lopatin, Ph.D. Department of Biologic.
1.1 Pathogens. Starter What is health? A state of complete physical, mental and social well- being. What is disease? A description of symptoms which suggest.
Chapter 18 Vaccines Termed coined by Pasteur to honor Jenner’s work Vaccines are cost-effective uses of our immune system Dramatic reduction of –Diptheria.
Immunity to microbes (mechanisms of defense against
Immunity to Infectious Diseases BIOS 486A/586A K.J.Goodrum 2006.
Lecture 9 immunology Protective Immunity To Microorganisms Dr. Dalia Galal.
Bacterial Physiology (Micr430) Lecture 18 Bacterial Pathogenesis (Based on other textbooks such as Madigan’s)
Introduction to Host-Microbe Interactions
General Microbiology (Micr300)
Immune Response and Immunity Envr 133 Mark D. Sobsey.
The Immune System. Immune System Our immune system is made up of: The innate immune system: first line of defence (non-specific) The adaptive immune system:
Vaccination. NATURALLY ACQUIRED IMMUNITY Active: Acquired through contact with microorganisms (infection). Provides long term protection. Passive: Antibodies.
Dennis E. Lopatin, Ph.D. Page no. 1 Anti-microbial activities of saliva.
BIO 411 – Medical Microbiology Chapter 9 Commensal and Pathogenic Microbial Flora.
Infection and Disease II Pathogenicity and Infection.
Sequencing capacitiesacademic company based microarray facilitiesacademic company based bioinformaticsacademic proteomic facilitiesacedemic Genome Research.
Immune response to infections. Factors influencing the extent and severity of infection Pathogen factors –Dose –Virulence of organism –Route of entry.
Immunoprevention. Definition By using immunological agents to construct, improve or inhibit immune response, people can prevent some diseases.
Musketeers Course October The Mucosal Immune System The organization of the mucosal immune systemThe organization of the mucosal immune system The.
Acquired Immunity. Acquired Immunity is more specialized than other mechanisms of immunity. Acquired Immunity may be a cell-mediated or it may be a humoral.
Lecture 14 Immunology: Adaptive Immunity. Principles of Immunity Naturally Acquired Immunity- happens through normal events Artificially Acquired Immunity-
Infectious Diarrheas - Overview Greatest cause of morbidity and mortality worldwide Scope of disease: 1993, E.coli 0157:H Cyclospora 1998.
Host-Parasite Relationship Normal Flora Pathogens Infections Opportunistic pathogens.
17-1 Topics Principals of immunization Vaccines Immunizations.
MLAB 2434 – CLINICAL MICROBIOLOGY SUMMER, 2005 CECILE SANDERS & KERI BROPHY Chapter 6 – Host-Parasite Interaction.
Defense &The Immune System Overview. Immune System Agenda The bigger picture Non specific defenses Specific defenses (Immunity)
Neonatal Immunology Kristina Abel, PhD CNPRC UC Davis How a Lymphomaniac views ( IL )lness.
Immunology 1 IMMUNOLOGY Sherko A Omer MB ChB, MSc., PhD.
HUMORAL IMMUNITY Primary molecular component: antibody
Reservoirs and vectors Reservoirs Animal, soil, water etc - source of infection. Vectors Arthropods, especially fleas, ticks, and mosquitoes Mechanical.
Infections: Evading Immune Systems
DR.FATIMA ALKHALEDY M.B.Ch.B;F.I.C.M.S/C.M.
14. Immunodiagnosis, Immunotherapy & Vaccination 王 家 鑫, MD College of Veterinary Medicine.
Chapter 17 Host- Microbe Interaction Biology 261 Medgar Evers College, CUNY Prof. Santos.
Molecular and Cellular Basis of Immune Protection of Mucosal Surfaces
Pamela A. Kozlowski 1 Marian R. Neutra 2 1 Children’s Hospital and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA. 2 Children’s.
Methods by which pathogens cause disease: Adhesion: bacteria must bind to the cell surfaces Colonization: bacteria produce proteins and colonize parts.
Commensal and Pathogenic Microbial Flora in Humans
MICROBIOLOGY ORAL MICROBIOLOGY AYDIN ÇÖL.
Pathogenesis of Infectious Diseases CLS 212: Medical Microbiology.
The different types of vaccines used and their composition.
Bacterial Interactions with Hosts. A. Terminology B. Hosts C. The Skin D. Oral cavity E. Intestinal Tract F. Respiratory Tract G. Genito-urinary Tract.
بسم اللة الرحمن الرحيم. Acquired Immunity Acquired (Adaptive) Immunity Defensive mechanisms include : Defensive mechanisms include : 1) Innate immunity.
Active immunity and vaccination What is immunisation? The process by which a person develops immunity to a disease causing organism. i.e. the blood contains.
Chemical plaque control
Medical Bacteriology MBIO 460 Lecture 9 Dr. Turki Dawoud 2 nd Semester 1436/1437 H.
MBBS Batch – 17 Remya APPLIED MICROBIOLOGY OF THE GIT.
 Gram-positive cocci in chains  Hemolytic exotoxin  Capsule  Serogroup based on M antigen  Group A:  Pharyngitis  Scarlet fever  Necrotizing fascitis.
Immunity in the oral cavity
IMMUNE RESPONSE AT MUCOSAL SURFACES
Chapter 12-Vaccines Traditional vs. rDNA vaccines Subunit vaccines
Chapter 16 Host- Microbe Interaction
Immune Response and Immunity
Immuoglobulin G (IgG).
CLS 223.
Pathogenesis of Infectious Diseases
lecture notes second med students- Vaccination
Defense &The Immune System
lecture notes second med students- Vaccination
Immunity to Infectious Diseases
Chapter 15 Microorganisms and Human Disease
Microorganisms and Disease
Microbial Mechanisms of Pathogenicity
Host Parasite Relationship
Presentation transcript:

Mucosal Vaccines: Prevention of Caries and Periodontal Diseases

Most infections occur or emanate from mucosal surfaces Gastrointestinal tract –Helicobacter pylori, Vibrio cholerae, enterotoxigenic E. coli, Salmonella, Shigella spp., Campylobacter jejuni, Clostridium difficile, rotaviruses, and calici viruses Respiratory tract –Mycoplasma pneumoniae, influenza virus, respiratory syncytial virus (RSV) Urogenital tract –HIV, Chlamydia, Neisseria gonorrhoeae, herpes simplex virus (HSV) and E. coli (urinary tract infections) Oral cavity –Streptococcus mutans, Porphyromonas gingivalis, Candida albicans

Goals for the development of a vaccine Prevent agent from attaching or colonizing the mucosal epithelium (non-invasive agents) Prevent penetration and replication within the mucosal epithelium (invasive agents) Block binding or action of toxin Induce a protective sIgA response Modulate systemic response?

Requirements of Protective Vaccines Block adherence of microorganism to host Facilitate clearance from host Neutralize toxin Must induce recognition of “virulence” epitopes Must be immunogenic Must not induce autoimmune disease Should induce long-lasting immunity Must induce the type of response that is effective to eliminate pathogen (eg. T H1 or T H2 )

Strategies for Mucosal Immunization Requirements – Safe taken orally – Long-term maintenance of memory – Survive in gastric and intestinal environments – Must escape normal clearance mechanisms – Must compete for inclusion within M-Cell transport – Must arrive intact to antigen-processing cells – Must induce dimeric sIgA reactive with cell surface

Strategies for Immunization (cont’d) Strategies for Delivery of Vaccine Into O-MALT – Inert particulate carriers Biodegradable copolymers Immune-stimulating complexes (ISCOMs) Hydroxyapatite crystals – Live vaccine vectors (recombinant) Vaccinia virus Salmonella Mycobacterium bovis

Strategies for Immunization (cont’d) Strategies for Enhancing Mucosal Immune Response – Co-delivery with cytokines – Co-immunogens (Cholera toxin) – Peptides presented with potent T-cell epitopes

Time course of sIgA appearance 3m6m2y?1m2-4w8w11w19w26w Gestation Birth SCBronchialEpithel-ium Peyer’sPatches SCSalivaryGland IgACells Saliva: Adult SC No IgA SalivasIgA Salivary Antibody to Initial Oral and Gut Flora Early IgA Peak ToothEruption Many Salivary IgA Concentrations in Adult Range AdultConcen-trations Adapted from Taubman & Smith, 1993

Issues in Oral Health Most oral infections are polymicrobial infections Most are chronic infections What is the etiologic agent? –Caries –Periodontal disease What are the virulence factors? What is the “at risk” population? Are there easier alternatives? Who do you immunize? Most are not life-threatening

What are the risks? Cross-reaction with host antigens Infection with live vaccines Syndromes

An example of a phase I anti-caries clinical trial Goal of study –Induction of sIgA by mucosal immunization with S. mutans antigen in lipid monolayer –Comparison of nasal vs. tonsillar immunization (topical spray) –Safety Antigen –E-GTF (enriched glucosyltransferase preparation) neet or in a liposomal vaccine preparation (lipid monolayer) Subjects –Twenty-one adults (20-50 years of age)

Goals (cont’d) Examine sIgA response in: –Parotid saliva –Nasal washes –Serum (IgG and IgA)

Protocol Samples collected at various intervals following immunization (0, one to two week intervals for three months)

Anti-GTF in Nasal washes Panels –Upper (IN immunized) No difference between soluble and liposomal –Lower (IT vs IN) Nasal better than tonsil

Anti-GTF in Parotid Saliva Panels –Upper (IN immunized) No difference between soluble and liposomal –Lower (IT vs IN) Nasal better than tonsil on day 35

Anti-GTF Serum Responses Panels –Upper (IgG response) Nasal better than tonsil Not statistically- significant –Lower (IgA response) Nasal better than tonsil Not statistically- significant

Conclusion Soluble and liposomal GTF appear to be safe Immunogenic when given in nasal route –In conflict with other studies These were adults, may be different in children